People · Operator
Named in public records as an officer, director or promoter · active 2012–2026 · Other Technology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nantero Inc | — | Other Technology | Series C | $172.9M | $1.4B | 2012 |
| Yuva Biosciences, Inc. | — | Biotech / Pharma | Series A | $5.6M | $2.6M | 2023 |
Greg Schmergel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Greg Schmergel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bruce Sachs | 1 | 10 |
| Jennifer Fonstad | 1 | 9 |
| Fred Ehrsam | 1 | 4 |
| Gregg Adkin | 1 | 4 |
| Michael Raam | 1 | 3 |
| Steve Wood | 1 | 3 |
| Andrew Goldfarb | 1 | 2 |
| Margaret Seif | 1 | 2 |
| David Poltack | 1 | 2 |
| Daniel Browne | 1 | 1 |
| Robert Snowberger | 1 | 1 |
| Daniel Marrujo | 1 | 1 |
| Michael Marquardt | 1 | 1 |
| Philipp Hensler | 1 | 1 |
| Richard Thurston | 1 | 1 |
| Trent Overhue | 1 | 1 |
| Ed Doller | 1 | 1 |
| OB Bilous | 1 | 1 |
| Dave Fachetti | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.